Biotech | January 20, 2026
DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Patients can now get the starting 2.5 mg dose for $299 per month
Companies in the pharmaceutical industry must shift from L1 (lowest-bid) costing to Life Cycle Cost Analysis (LCCA) to achieve long-term cost optimization, improve decision-making, and enhance sustainability
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Jaypirca is making waves in the fight against B-cell malignancies
Subscribe To Our Newsletter & Stay Updated
